Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

about

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

Item

http://www.wikidata.org/entity/Q57486475

description

scientific article published on 01 October 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

@en

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

@nl

type

Item

label

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

@en

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

@nl

prefLabel

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

@en

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

@nl

P1476

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

@en

P2093

Gerty Schreibelt

http://www.w3.org/2001/XMLSchema#string

I Jolanda M de Vries

http://www.w3.org/2001/XMLSchema#string

Martine Bloemendal

http://www.w3.org/2001/XMLSchema#string

Winald R Gerritsen

http://www.w3.org/2001/XMLSchema#string

Wouter W van Willigen

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

Toxicities of Immunotherapy for the Practitioner

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Dendritic cells and the control of immunity

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

P304

2265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2018.02265

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kalijn Bol

P577

2018-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30327656

http://www.w3.org/2001/XMLSchema#string

P932

6174277

http://www.w3.org/2001/XMLSchema#string